role of vitamin D and zinc in the treatment of severe pneumonia in children age between 2 months to 5 years

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/033062

Enrollment

150

Registered

2021-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: J159- Unspecified bacterial pneumonia

Interventions

Intervention1: vitamin D and zinc: role of vitamin D and zinc in pneumonia in children aged between 2 months to 5 years Intervention2: Zinc and IV antibiotics: Receiving oral zinc ( 10 mg/ day for p

20 mg/ day for patients more than 6 months ) for 2 weeks with IV antibiotics Intervention3: Vitamin D and IV antibiotics: Receiving oral vitamin D (1000 IU for patients of age less than 1 year and 2

20 mg/ day for patients more than 6 months ) for 2 weeks AND receiving oral vitamin D (1000 IU for patients with age less than 1 year and 2000 IU for patients with age more than 1 year) for 4 days and

Eligibility

Inclusion criteria

Inclusion criteria: Children aged between 2 months to 5 years with a clinical diagnosis of severe pneumonia ( clinical presentation with cough, fever, tachypnia and crepitations on auscultation along with presence of either lower chest indrawing or atleast one of danger sign( inability to feed, lethargy, cyanosis). Chest x ray findings: shadowing (patchy/ diffuse) / pleural effusion/ hyperinflation/atelectasis/pneumothorax/ hilar adenopathy/ bronchovascular marking/ others.

Exclusion criteria

Exclusion criteria: Receipt of vitaminD or calcium supplementation and zinc within last 4 weeks before admission. Severe malnutrition. Known asthmatics. Concurrent empyema or Illness severe anough to require ventilation. Clinical evidence of any heart disease, renal or hepatic insufficiency and known hypercalcemia of allergy to vitamin D and Zinc

Design outcomes

Primary

Measure	Time frame
Time of resolution of severe pneumonia (considered when lower chest retraction and danger signs (inability to feed, lethargy, cyanosis or hypoxia) are no longer present. This will be measured in hours.Timepoint: Time of resolution of severe pneumonia will be assessed every 8 hourly from time of enrollment.	—

Secondary

Measure	Time frame
Duration of symptoms of pneumonia ( tachypnea , lower chest retraction and abnormal chest x ray findings) and the duration of hospital stay which will be defined as the time in hours between study enrolment and discharge.Timepoint: number of days of hospital stay	—

Countries

India

Contacts

Public ContactDr Mukesh Vir Singh MD DCH

Motilal Nehru Medical College, Allahabad

mukeshvirsingh@gmail.com9456630304

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026